BTG Pactual Asset Management US’s Regeneron Pharmaceuticals REGN Stock Holding History

BTG Pactual Asset Management US’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$369K	Buy	+591	New	+$402K	0.02%	307

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

BTG Pactual Asset Management US's REGN Position: Q2 2026 in Review

BTG Pactual Asset Management US opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2026: 591 shares worth $369K. The stake represents 0.02% of the portfolio and ranks #307 among its holdings.

1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

BTG Pactual Asset Management US held 591 shares of Regeneron Pharmaceuticals worth $369K as of Q2 2026.
Regeneron Pharmaceuticals was a new BTG Pactual Asset Management US position in Q2 2026.
Regeneron Pharmaceuticals made up 0.02% of BTG Pactual Asset Management US's portfolio in Q2 2026, its #307 holding.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on BTG Pactual Asset Management US's 13F filing for Q2 2026, filed 14 Aug 2026.